Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

6 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single-cell analysis of T-cells from mouse neonate thymuses in a wild type control and a placental specific isoform of Igf2 knock-down (igf2-P0)

ABSTRACT: Fetal growth restriction (FGR) causes a wide variety of developmental defects in the neonate which can lead to heart disease, diabetes, anxiety and other disorders later in life. The effect of FGR on the immune system, however, is poorly understood. Immune cells throughout development are identified using cell-surface markers to distinguish between subtly different stages. These (surface) proteins, however, do not necessarily generate differences in cellular activity and may thus be only a coincidental shallow guide to classifying cells. High-throughput single-cell transcriptomics using DropSeq was performed on mouse neonate thymuses. The T-cell population was selected through flow cytometry in wild type controls and a placental specific isoform of Igf2 knock-down (igf2-p0). Using this analysis, we discovered skewed T-cell populations in the growth restricted murine neonate indicating a developmental delay. This finding recapitulates the altered immunity found in growth restricted human infants. The T-cell deficit persisted into adulthood, even when body and organ weights approached normal levels due to catch-up growth. This reduction in T-cellularity may have significant implications in adult immunity, adding to the wide variety of fetal origins for adult disease already known.

INSTRUMENT(S): Illumina HiSeq 4000

ORGANISM(S): Mus musculus

SUBMITTER: Wendi Bacon

PROVIDER: E-MTAB-6945 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

IGF2 shRNA knockdown in the colorectal cancer (CRC) cell line SW480

Project description:In order to identify gene expression changes associated with the deregulated of IGF2, Doxycylin inducible empty vector and IGF2 shRNA permanent cell lines were generated by lentivral transduction in the colorectal cancer (CRC) cell line SW480 and selected with puromycin. For microarray analysis, both cell lines were plated at 3 x 105 cells in 6 well plates using RPMI plus 10% FCS and penicillin/ streptomycin, either without/ with 50 ng/ ml doxycycline at the time of plating. The respective cell lines were harvested at day 1, 3, and 5. Three experiments were performed for each time point and condition and were separately analyzed. The samples were analyzed on Illumina human HT-12 v 4 expression bead chips. The microarray data was processed and normalized using the lumi pipline.

2016-04-30 | E-MTAB-3786 | biostudies-arrayexpress

Gene expression profiles of dental follicle cells after 7 days of differentiation in vitro with BMP2, IGF2 and dexamethasone

Project description:We analysed gene expression profiles in dental follicle cells after 7 days of osteogenic differentiation with different inducers. Total RNAs were isolated from dental follicle cells after 7 days of differentiation with dexamethasone, BMP2, IGF2 and for control with standard cell culture medium

2010-11-10 | E-GEOD-20963 | biostudies-arrayexpress

Secretome and phosphoproteome analysis of THP-1 and KOPN-8 cells treated with Insulin-like growth factor 2.

Project description:We describe the secretome and phosphoproteome of human leukemia cell lines, THP-1 and KOPN-8, treated with Insulin-like growth factor 2 (IGF2) using data-independent acquisition mass spectrometry analysis.

2024-04-02 | PXD049016 | Pride

Mesenchymal Igf2 is a major regulator of pancreatic growth and function

Project description:The genetic mechanisms that determine the size of the adult pancreas are not fully understood. Here we address the importance of the imprinted Igf2 gene for growth and function of the mouse pancreas. We used reporter lines to monitor Igf2 levels during late fetal and postnatal pancreatic development and demonstrate that Igf2 is mostly expressed within the mesenchyme. We manipulated Igf2 levels in vivo in the major pancreas cell types using Cre lines and found that loss of Igf2 from the developing mesenchyme results in pancreatic hypoplasia, associated with loss of acinar and beta-cell mass, postnatal whole-body growth restriction and maternal glucose intolerance during pregnancy. Overexpression of Igf2 directed to the mesenchyme results in pancreatic overgrowth. Importantly, deletion of Igf2 from the developing epithelium has no growth effects. Our findings demonstrate that a major role for Igf2 is the regulation of pancreas size, and reveal an unforeseen key function for mesenchymal IGF signalling in pancreatic growth.

2017-12-31 | GSE100981 | GEO

Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells.

Project description:The transcription factor nuclear factor-κB (NF-κB) has important roles for tumorigenesis, but how it regulates cancer stem cells (CSCs) remains largely unclear. We identified insulin-like growth factor 2 (IGF2) is a key target of NF-κB activated by HER2/HER3 signaling to form tumor spheres in breast cancer cells. The IGF2 receptor, IGF1 R, was expressed at high levels in CSC-enriched populations in primary breast cancer cells. Moreover, IGF2-PI3K (IGF2-phosphatidyl inositol 3 kinase) signaling induced expression of a stemness transcription factor, inhibitor of DNA-binding 1 (ID1), and IGF2 itself. ID1 knockdown greatly reduced IGF2 expression, and tumor sphere formation. Finally, treatment with anti-IGF1/2 antibodies blocked tumorigenesis derived from the IGF1Rhigh CSC-enriched population in a patient-derived xenograft model. Thus, NF-κB may trigger IGF2-ID1-IGF2-positive feedback circuits that allow cancer stem-like cells to appear. Then, they may become addicted to the circuits. As the circuits are the Achilles' heels of CSCs, it will be critical to break them for eradication of CSCs.

2016-09-05 | GSE64073 | GEO

Urinary Glycosylated IGF2 peptides in association with CKD

Project description:Chronic kidney disease (CKD) is prevalent in 10% of world’s adult population, with Estimated Glomerular filtration rate (eGFR) and albuminuria employed in diagnosis. Role of protein glycosylation in causal mechanisms of CKD progression is largely unknown. Aim of this study was to identify urinary O-linked glycopeptides in association to CKD for better characterization of CKD molecular manifestations. Urine samples from 2 healthy and 8 CKD subjects were analyzed by CE-MS/MS and glycopeptide analysis using Proteome Discoverer 1.4. Distribution of identi-fied glycopeptides and correlation with Age, eGFR and Albuminuria were evaluated in 3810 da-tasets. In total, 17 O-linked glycopeptides from 7 different proteins were identified, derived primarily from Insulin-like growth factor-II (IGF2). Glycosylation occurred at the surface ex-posed IGF2 Threonine 96 position. Three glycopeptides (DVStPPTVLPDNFPRYPVGKF, DVStPPTVLPDNFPRYPVG and DVStPPTVLPDNFPRYP) exhibited positive correlation with Age. Glycopeptide (tPPTVLPDNFPRYP) showed strong negative association with eGFR. These results suggest that with aging and deteriorating kidney function, alterations in IGF2 proteoforms take place; which may reflect changes in mature IGF2 protein. Our results corroborate this hypothesis as IGF2 increased plasma levels were observed in CKD patients. Protease predictions, consider-ing also available transcriptomics data, suggest activation of cathepsin S with CKD, meriting further investigation.

2023-05-10 | PXD039829 | Pride

KRAB-ZFP/KAP1 is essential to restrict excessive IGF2 expression during mouse embryo development

Project description:Insulin-like growth factor 2 (Igf2) is the major fetal growth hormone in mammals. Here we identify the Kruppel-associated-box (KRAB) zinc finger protein 568 (ZFP568) as a direct repressor of a placental specific Igf2 transcript (designated Igf2-P0) in early mouse development. Loss of Zfp568, which leads to gastrulation failure, causes inappropriate Igf2-P0 activation. Strikingly, deletion of paternal Igf2 can completely rescue Zfp568 knockout-induced gastrulation phenotypes. Mechanistically, ZFP568 and its binding site are required to maintain H3K9me3 and CpG methylation of the Igf2-P0 region. The ZFP568 binding site upstream of the Igf2-P0 transcript is highly conserved throughout Eutheria, along with the DNA binding domain of ZFP568 orthologs, with the exception of human, whose three Znf568 alleles previously linked to human head size at birth have rapidly evolved and mostly lost the ability to bind and suppress Igf2, coincident with the loss of Igf2-P0 transcript activity. We speculate that the Igf2-P0 transcript and its repressor ZFP568 appeared in a common ancestor of placental mammals as a critical adaptation to boost Igf2 expression specifically in the placenta to regulate maternal supply and fetal demand for nutrients. These data also highlight the exquisite specificity and selectivity by which KRAB-ZFPs have been naturally selected to recognize their genomic targets for pinpoint heterochromatin establishment during mammalian evolution.

2017-05-17 | GSE84832 | GEO

Microarray expression profiling of the Igf2 pathway dependency of Trp53 developmental and tumour phenotypes in mice

Project description:We tested whether loss of p53 function leads to insulin-like growth factor 2 (IGF2) pathway dependency in vivo in genetically defined mouse models. Unexpectedly we found lethality, due to post-natal lung haemorrhage, occurred in Igf2 paternal null allele female mice (Igf2-p) but only if derived from double heterozygote fathers (Igf2-p, p53+/-). Consequently we investigated the effects of paternal genotype (wild-type, Igf2-p and Igf2-p, p53+/-) on gene expression. Microarray gene expression profiling of whole mouse embryos (embryonic day 9.5) revealed that lethality was associated with a specific gene signature. Since double heterozygote female offspring (Igf2-p, p53+/-) of Igf2-p, p53+/- fathers did not have the lethality phenotype we identified gene expression changes associated with this 'rescue'. Supplementary information available when browsing all available files.

2012-06-01 | E-MTAB-1001 | biostudies-arrayexpress

Synaptosome proteome IGF2 enhancer knockout mice

Project description:We identified an enhancer element near IGF2 locus that is possibly involved with dopamine function and schizophrenia. A knockout mouse was generated for the enhancer element in the IGF2 locus. We then characterized the striatal synaptosomes ( i.e. biological fraction representing pre- post synaptic nerve terminal)by mass spectometry from WT and Igf2 enhancer KO mice.

2019-05-31 | PXD012786 | Pride

IGF2 is an epi-driver and therapeutic target in hepatocellular carcinoma

Project description:Background & Aims: Hepatocellular carcinoma (HCC) is a major health problem. Most patients are diagnosed at advanced stages when the only approved therapy is sorafenib. Consequently, there is an urgent need to develop effective treatments. IGF-signaling is aberrantly activated in HCC, but there is no clear understanding on the molecular drivers and potential therapeutic targets within the pathway. Since IGF2-ligand is overexpressed in HCC, we aimed to elucidate its mechanism of overexpression, assess its oncogenic potential in vitro and in vivo and determine the antitumoral efficacy of molecular therapies against IGF2. Methods: Expression profiling, miRNAs expression and methylation were analyzed in 228 HCCs focusing on IGF2. Stable HCC cell lines with knock-down and ectopic overexpression of IGF2 were generated. A chemically-induced mouse model of HCC, and genetically-engineered mouse models (GEMM) overexpressing IGF2 in the liver were generated to assess IGF2 oncogenicity. The therapeutic potential of the monoclonal antibody against IGF-ligands (IGF1/2-mAb) and its combination with sorafenib was tested in vitro and in a xenograft model. Results: IGF2-overexpression occurred in 15% of HCC patients as a result of the epigenetic reactivation of IGF2-fetal promoters, mainly through loss of promoter methylation. Re-expression of IGF2 was associated with progenitor cell-like and poorly differentiated HCCs, and with poor prognosis (p<0.0001). In the GEMM model, IGF2-overexpression accelerated HCC progression and reduced survival (p=0.02). Conversely, IGF2-blockage using IGF1/2- mAbs delayed tumor growth and increased survival in vivo (p<0.0001), through antiproliferative and antiangiogenic mechanisms. Conclusions: We propose IGF2 as the first actionable epi-driver in HCC, and IGF1/2-mAbs as a potential targeted therapy in a defined subset of HCC patients. Keywords: IGF2, HCC, epidriver, IGF-pathway, monoclonal antibody, BI 836845.

2019-08-05 | GSE85274 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data